Company Insights

SMTI customer relationships

Explore interactive graphBrowse insights index
SMTI customer relationship map

Sanara MedTech (SMTI): Customer relationships, contracting posture, and commercial implications for investors

Sanara MedTech develops, markets and distributes surgical, skin and wound care products and monetizes via product sales through its Sanara Surgical commercial segment, third‑party distributors and institutional contracting. Revenue is driven by product placement in hospitals and surgical centers, expanded distributor coverage and selective contracting with large purchasing networks (for example, Vizient). For investors, the key questions are how repeatable sales are under existing contracting terms, how distribution relationships scale clinical adoption, and whether purchasing-network wins convert into sustained, material revenue growth. For a focused look at customer relationships and what they imply for valuation and execution, read on — and you can explore the full research platform here: https://nullexposure.com/.

Why customer relationships move the needle for SMTI

Sanara’s business model is fundamentally commercial: it translates innovation (products such as BIASURGE and other surgical wound care offerings) into hospital and clinic placements that generate recurring consumable revenue. Contracting posture, distributor coverage and access to large group purchasing networks are the operational levers that determine top‑line durability. The company’s filings and press releases show a mix of internal sales channels and strategic third‑party access deals that together shape growth potential.

The customer roster: what the filings and press say

Sanara Surgical — the revenue engine inside the company

Sanara Surgical is the company’s operating segment responsible for marketing and distributing surgical, wound and skincare products, and the company reports that all net revenue for both 2023 and 2024 was generated from Sanara Surgical, making it the operational locus of commercial activity. This disclosure comes from Sanara MedTech’s 2024 Form 10‑K filing. (Source: 2024 Form 10‑K).

Vizient, Inc. — network access for BIASURGE beginning 2026

Sanara announced that its BIASURGE Advanced Surgical Solution received an Innovative Technology contract from Vizient, which gives Vizient’s network of provider members access to BIASURGE at contracted pricing and pre‑negotiated terms effective January 1, 2026. The company communicated this in January 2026 press releases on GlobeNewswire and other outlets. This is a distribution/market‑access win that shortens procurement friction for hospital buyers. (Source: GlobeNewswire press releases, January 7 and January 23, 2026).

Scendia Biologics, LLC — prior sub‑distributor and joint‑venture partner (acquired)

Before being acquired by Sanara, Scendia served as a sub‑distributor and joint‑venture partner for the company’s products, a relationship noted in Sanara’s announcement of the Scendia acquisition in July 2022. The acquisition consolidated a portion of Sanara’s distribution network under direct ownership. (Source: GlobeNewswire press release, July 5, 2022).

What the relationship set reveals about Sanara’s operating model

The combined record of internal segment sales (Sanara Surgical), distributor relationships and a Vizient contracting win produces several clear operating signals:

  • Contracting posture — skewed toward multi‑year, institutional engagements. Company commentary indicates customer contracts in a three‑to‑five‑year range as a working assumption for its commercial model, which supports investment in clinical training and rep coverage without constant renegotiation.
  • Commercial sophistication — value‑oriented pricing under consideration. Company disclosures reference a mix of episodic and value‑based pricing approaches (including per‑member‑per‑month and fee‑for‑value constructs), suggesting Sanara is structuring pricing to align with outcomes and institutional workflows rather than just unit selling price.
  • Geographic concentration — U.S. surgical and wound markets. Product sales are primarily in the United States surgical tissue repair and advanced wound care markets, indicating growth is tied to U.S. hospital penetration and reimbursement dynamics.
  • Customer concentration — low external concentration risk. The company reports no customer in 2024 that accounted for at least 10% of annual sales or receivables, which limits single‑buyer negotiating leverage over pricing and cash flow.
  • Distribution posture — hybrid direct/third‑party with consolidation activity. Sanara sells through a network of surgical specialty distributors and company representatives, and it has moved to consolidate elements of that network via acquisitions such as Scendia.

These signals combine into a profile of a commercializing medtech company that relies on longer contract tenors and institutional access deals (like Vizient) to scale, while retaining flexibility through distributor relationships and occasional strategic acquisitions. If you want to track changes in contracting or network wins for competitive edge, visit https://nullexposure.com/.

How these relationships affect upside and risk

  • Upside: Vizient contracting accelerates purchasing‑path adoption and reduces procurement friction across a broad hospital network, improving path to scale for BIASURGE. Consolidating distributors through M&A (Scendia) increases control over selling economics and margin capture.
  • Operational risk: Execution depends on converting institutional contracting and distributor reach into consistent order flow; long sales cycles and the need for clinical adoption can slow revenue realization even after contract awards. The company’s gross profit profile is strong relative to revenue, but net profitability has not yet fully converted (company financials reflect negative EPS on trailing twelve‑month basis).
  • Concentration tradeoff: While no single external customer exceeds 10% of sales (limiting buyer concentration risk), the company is effectively concentrated in its Sanara Surgical segment as the singular revenue engine, making segment execution a single point of failure if product adoption stalls.

Tactical investor takeaways and recommended actions

  • Focus on conversion metrics: Watch order and shipment cadence in the quarters following the Vizient award — contracted access is necessary but not sufficient; conversion into sustained purchase volume is the catalyst for re‑rating.
  • Monitor distributor economics: Track margins and gross‑to‑net dynamics as Sanara integrates acquired distributor assets and executes exclusive distribution agreements.
  • Validate contracting maturity: Confirm that the stated three‑to‑five‑year contracting posture and value‑based pricing initiatives translate into recurring revenue and lower churn.

For ongoing signals and to compare Sanara’s contracting and customer network against peers, visit the research hub at https://nullexposure.com/.

Bottom line

Sanara MedTech’s customer footprint is defined by an internal commercial segment (Sanara Surgical), strategic network access (Vizient Innovative Technology contract), and consolidation of distribution (Scendia acquisition). The company’s model prizes long‑tenor institutional contracts and distributor reach over single large buyers, which reduces customer concentration risk but places execution emphasis on converting institutional access into repeatable revenue. Investors should measure success by contract conversions, distributor margin trends and post‑award purchase behavior. For continuous monitoring and deeper relationship analytics, start here: https://nullexposure.com/.